Chimerix shares crash as antiviral flops and deaths spike in first PhIII challenge

John Carroll

High hopes for 's turned into a bad case of data shock Monday morning after the biotech revealed that brincidofovir had failed its Phase III study. The stock instantly plunged, erasing 79% of its value by midmorning as investors absorbed the news of the setback and the company halted enrollment in two other late-stage transplant trials.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS